JP6548632B2 - 治療用化合物の生物学的利用能を向上させるための産物および方法 - Google Patents
治療用化合物の生物学的利用能を向上させるための産物および方法 Download PDFInfo
- Publication number
- JP6548632B2 JP6548632B2 JP2016503442A JP2016503442A JP6548632B2 JP 6548632 B2 JP6548632 B2 JP 6548632B2 JP 2016503442 A JP2016503442 A JP 2016503442A JP 2016503442 A JP2016503442 A JP 2016503442A JP 6548632 B2 JP6548632 B2 JP 6548632B2
- Authority
- JP
- Japan
- Prior art keywords
- curcumin
- solution
- milk protein
- protein concentrate
- target compound
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 238000000034 method Methods 0.000 title claims description 70
- 150000001875 compounds Chemical class 0.000 title description 81
- 230000001225 therapeutic effect Effects 0.000 title description 8
- 230000002708 enhancing effect Effects 0.000 title description 4
- VFLDPWHFBUODDF-FCXRPNKRSA-N curcumin Chemical compound C1=C(O)C(OC)=CC(\C=C\C(=O)CC(=O)\C=C\C=2C=C(OC)C(O)=CC=2)=C1 VFLDPWHFBUODDF-FCXRPNKRSA-N 0.000 claims description 173
- 108010011756 Milk Proteins Proteins 0.000 claims description 94
- 102000014171 Milk Proteins Human genes 0.000 claims description 94
- 235000021239 milk protein Nutrition 0.000 claims description 94
- 239000012141 concentrate Substances 0.000 claims description 91
- 235000012754 curcumin Nutrition 0.000 claims description 85
- 229940109262 curcumin Drugs 0.000 claims description 85
- 239000004148 curcumin Substances 0.000 claims description 85
- VFLDPWHFBUODDF-UHFFFAOYSA-N diferuloylmethane Natural products C1=C(O)C(OC)=CC(C=CC(=O)CC(=O)C=CC=2C=C(OC)C(O)=CC=2)=C1 VFLDPWHFBUODDF-UHFFFAOYSA-N 0.000 claims description 84
- 239000000693 micelle Substances 0.000 claims description 47
- 239000005018 casein Substances 0.000 claims description 32
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 claims description 31
- 235000021240 caseins Nutrition 0.000 claims description 31
- 238000002156 mixing Methods 0.000 claims description 26
- 238000001816 cooling Methods 0.000 claims description 22
- 239000002245 particle Substances 0.000 claims description 19
- 235000018102 proteins Nutrition 0.000 claims description 15
- 102000004169 proteins and genes Human genes 0.000 claims description 15
- 108090000623 proteins and genes Proteins 0.000 claims description 15
- 238000010438 heat treatment Methods 0.000 claims description 13
- 239000000843 powder Substances 0.000 claims description 13
- 238000001035 drying Methods 0.000 claims description 9
- 238000001694 spray drying Methods 0.000 claims description 9
- 238000000227 grinding Methods 0.000 claims description 6
- 239000000243 solution Substances 0.000 description 57
- 239000000047 product Substances 0.000 description 24
- 210000004027 cell Anatomy 0.000 description 17
- 230000008569 process Effects 0.000 description 11
- 235000020183 skimmed milk Nutrition 0.000 description 10
- CWVRJTMFETXNAD-FWCWNIRPSA-N 3-O-Caffeoylquinic acid Natural products O[C@H]1[C@@H](O)C[C@@](O)(C(O)=O)C[C@H]1OC(=O)\C=C\C1=CC=C(O)C(O)=C1 CWVRJTMFETXNAD-FWCWNIRPSA-N 0.000 description 8
- PZIRUHCJZBGLDY-UHFFFAOYSA-N Caffeoylquinic acid Natural products CC(CCC(=O)C(C)C1C(=O)CC2C3CC(O)C4CC(O)CCC4(C)C3CCC12C)C(=O)O PZIRUHCJZBGLDY-UHFFFAOYSA-N 0.000 description 8
- CWVRJTMFETXNAD-KLZCAUPSSA-N Neochlorogenin-saeure Natural products O[C@H]1C[C@@](O)(C[C@@H](OC(=O)C=Cc2ccc(O)c(O)c2)[C@@H]1O)C(=O)O CWVRJTMFETXNAD-KLZCAUPSSA-N 0.000 description 8
- 235000001368 chlorogenic acid Nutrition 0.000 description 8
- CWVRJTMFETXNAD-JUHZACGLSA-N chlorogenic acid Chemical compound O[C@@H]1[C@H](O)C[C@@](O)(C(O)=O)C[C@H]1OC(=O)\C=C\C1=CC=C(O)C(O)=C1 CWVRJTMFETXNAD-JUHZACGLSA-N 0.000 description 8
- 229940074393 chlorogenic acid Drugs 0.000 description 8
- FFQSDFBBSXGVKF-KHSQJDLVSA-N chlorogenic acid Natural products O[C@@H]1C[C@](O)(C[C@@H](CC(=O)C=Cc2ccc(O)c(O)c2)[C@@H]1O)C(=O)O FFQSDFBBSXGVKF-KHSQJDLVSA-N 0.000 description 8
- BMRSEYFENKXDIS-KLZCAUPSSA-N cis-3-O-p-coumaroylquinic acid Natural products O[C@H]1C[C@@](O)(C[C@@H](OC(=O)C=Cc2ccc(O)cc2)[C@@H]1O)C(=O)O BMRSEYFENKXDIS-KLZCAUPSSA-N 0.000 description 8
- 235000013336 milk Nutrition 0.000 description 7
- 239000008267 milk Substances 0.000 description 7
- 210000004080 milk Anatomy 0.000 description 7
- 239000000203 mixture Substances 0.000 description 7
- 238000009928 pasteurization Methods 0.000 description 7
- AAWZDTNXLSGCEK-LNVDRNJUSA-N (3r,5r)-1,3,4,5-tetrahydroxycyclohexane-1-carboxylic acid Chemical compound O[C@@H]1CC(O)(C(O)=O)C[C@@H](O)C1O AAWZDTNXLSGCEK-LNVDRNJUSA-N 0.000 description 6
- AAWZDTNXLSGCEK-UHFFFAOYSA-N Cordycepinsaeure Natural products OC1CC(O)(C(O)=O)CC(O)C1O AAWZDTNXLSGCEK-UHFFFAOYSA-N 0.000 description 6
- AAWZDTNXLSGCEK-ZHQZDSKASA-N Quinic acid Natural products O[C@H]1CC(O)(C(O)=O)C[C@H](O)C1O AAWZDTNXLSGCEK-ZHQZDSKASA-N 0.000 description 6
- 150000002989 phenols Chemical class 0.000 description 6
- 235000013824 polyphenols Nutrition 0.000 description 6
- 239000007787 solid Substances 0.000 description 6
- QAIPRVGONGVQAS-DUXPYHPUSA-N trans-caffeic acid Chemical compound OC(=O)\C=C\C1=CC=C(O)C(O)=C1 QAIPRVGONGVQAS-DUXPYHPUSA-N 0.000 description 6
- 238000005119 centrifugation Methods 0.000 description 5
- -1 curcuminoids Chemical compound 0.000 description 5
- 238000010792 warming Methods 0.000 description 5
- 241000894006 Bacteria Species 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 4
- 206010028980 Neoplasm Diseases 0.000 description 4
- 238000010521 absorption reaction Methods 0.000 description 4
- 230000008901 benefit Effects 0.000 description 4
- 201000011510 cancer Diseases 0.000 description 4
- 230000002209 hydrophobic effect Effects 0.000 description 4
- 230000035699 permeability Effects 0.000 description 4
- 150000007965 phenolic acids Chemical class 0.000 description 4
- 150000008442 polyphenolic compounds Chemical class 0.000 description 4
- PCMORTLOPMLEFB-ONEGZZNKSA-N sinapic acid Chemical compound COC1=CC(\C=C\C(O)=O)=CC(OC)=C1O PCMORTLOPMLEFB-ONEGZZNKSA-N 0.000 description 4
- ACEAELOMUCBPJP-UHFFFAOYSA-N (E)-3,4,5-trihydroxycinnamic acid Natural products OC(=O)C=CC1=CC(O)=C(O)C(O)=C1 ACEAELOMUCBPJP-UHFFFAOYSA-N 0.000 description 3
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 3
- 241000700159 Rattus Species 0.000 description 3
- 108010046377 Whey Proteins Proteins 0.000 description 3
- 239000002671 adjuvant Substances 0.000 description 3
- 235000004883 caffeic acid Nutrition 0.000 description 3
- 229940074360 caffeic acid Drugs 0.000 description 3
- 235000013985 cinnamic acid Nutrition 0.000 description 3
- QAIPRVGONGVQAS-UHFFFAOYSA-N cis-caffeic acid Natural products OC(=O)C=CC1=CC=C(O)C(O)=C1 QAIPRVGONGVQAS-UHFFFAOYSA-N 0.000 description 3
- 235000013305 food Nutrition 0.000 description 3
- 210000000936 intestine Anatomy 0.000 description 3
- 239000008101 lactose Substances 0.000 description 3
- WBYWAXJHAXSJNI-UHFFFAOYSA-N methyl p-hydroxycinnamate Natural products OC(=O)C=CC1=CC=CC=C1 WBYWAXJHAXSJNI-UHFFFAOYSA-N 0.000 description 3
- 235000004252 protein component Nutrition 0.000 description 3
- 239000007921 spray Substances 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 238000000108 ultra-filtration Methods 0.000 description 3
- 235000021119 whey protein Nutrition 0.000 description 3
- KSEBMYQBYZTDHS-HWKANZROSA-M (E)-Ferulic acid Natural products COC1=CC(\C=C\C([O-])=O)=CC=C1O KSEBMYQBYZTDHS-HWKANZROSA-M 0.000 description 2
- WBYWAXJHAXSJNI-VOTSOKGWSA-M .beta-Phenylacrylic acid Natural products [O-]C(=O)\C=C\C1=CC=CC=C1 WBYWAXJHAXSJNI-VOTSOKGWSA-M 0.000 description 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
- 208000017667 Chronic Disease Diseases 0.000 description 2
- WBYWAXJHAXSJNI-SREVYHEPSA-N Cinnamic acid Chemical compound OC(=O)\C=C/C1=CC=CC=C1 WBYWAXJHAXSJNI-SREVYHEPSA-N 0.000 description 2
- 235000003392 Curcuma domestica Nutrition 0.000 description 2
- 244000008991 Curcuma longa Species 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 102000007544 Whey Proteins Human genes 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical class OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 239000011575 calcium Substances 0.000 description 2
- 229910052791 calcium Inorganic materials 0.000 description 2
- 239000013553 cell monolayer Substances 0.000 description 2
- 229930016911 cinnamic acid Natural products 0.000 description 2
- 235000003373 curcuma longa Nutrition 0.000 description 2
- 235000013365 dairy product Nutrition 0.000 description 2
- 238000011026 diafiltration Methods 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- KSEBMYQBYZTDHS-HWKANZROSA-N ferulic acid Chemical compound COC1=CC(\C=C\C(O)=O)=CC=C1O KSEBMYQBYZTDHS-HWKANZROSA-N 0.000 description 2
- 235000001785 ferulic acid Nutrition 0.000 description 2
- 229940114124 ferulic acid Drugs 0.000 description 2
- KSEBMYQBYZTDHS-UHFFFAOYSA-N ferulic acid Natural products COC1=CC(C=CC(O)=O)=CC=C1O KSEBMYQBYZTDHS-UHFFFAOYSA-N 0.000 description 2
- 229930003935 flavonoid Natural products 0.000 description 2
- 150000002215 flavonoids Chemical class 0.000 description 2
- 235000017173 flavonoids Nutrition 0.000 description 2
- 210000001035 gastrointestinal tract Anatomy 0.000 description 2
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 2
- 239000010931 gold Substances 0.000 description 2
- 229910052737 gold Inorganic materials 0.000 description 2
- 229910052500 inorganic mineral Inorganic materials 0.000 description 2
- 238000011835 investigation Methods 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 239000011707 mineral Substances 0.000 description 2
- 239000002105 nanoparticle Substances 0.000 description 2
- 239000003921 oil Substances 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N phenol group Chemical group C1(=CC=CC=C1)O ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- 235000009048 phenolic acids Nutrition 0.000 description 2
- PCMORTLOPMLEFB-UHFFFAOYSA-N sinapinic acid Natural products COC1=CC(C=CC(O)=O)=CC(OC)=C1O PCMORTLOPMLEFB-UHFFFAOYSA-N 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- QURCVMIEKCOAJU-UHFFFAOYSA-N trans-isoferulic acid Natural products COC1=CC=C(C=CC(O)=O)C=C1O QURCVMIEKCOAJU-UHFFFAOYSA-N 0.000 description 2
- 235000013976 turmeric Nutrition 0.000 description 2
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- 208000002874 Acne Vulgaris Diseases 0.000 description 1
- 208000030090 Acute Disease Diseases 0.000 description 1
- 208000024827 Alzheimer disease Diseases 0.000 description 1
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 201000004624 Dermatitis Diseases 0.000 description 1
- 108010008165 Etanercept Proteins 0.000 description 1
- 208000010201 Exanthema Diseases 0.000 description 1
- 108090000386 Fibroblast Growth Factor 1 Proteins 0.000 description 1
- 102100031706 Fibroblast growth factor 1 Human genes 0.000 description 1
- 101000851181 Homo sapiens Epidermal growth factor receptor Proteins 0.000 description 1
- 101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 239000005551 L01XE03 - Erlotinib Substances 0.000 description 1
- 208000019693 Lung disease Diseases 0.000 description 1
- 208000012902 Nervous system disease Diseases 0.000 description 1
- 208000025966 Neurological disease Diseases 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- 201000004681 Psoriasis Diseases 0.000 description 1
- 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 1
- MECHNRXZTMCUDQ-UHFFFAOYSA-N Vitamin D2 Natural products C1CCC2(C)C(C(C)C=CC(C)C(C)C)CCC2C1=CC=C1CC(O)CCC1=C MECHNRXZTMCUDQ-UHFFFAOYSA-N 0.000 description 1
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 206010000496 acne Diseases 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 230000000843 anti-fungal effect Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 229940120638 avastin Drugs 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 235000011089 carbon dioxide Nutrition 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000004700 cellular uptake Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 238000010668 complexation reaction Methods 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 239000003599 detergent Substances 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 230000003292 diminished effect Effects 0.000 description 1
- 208000016097 disease of metabolism Diseases 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 229940073621 enbrel Drugs 0.000 description 1
- 238000005538 encapsulation Methods 0.000 description 1
- 125000002587 enol group Chemical group 0.000 description 1
- 210000000981 epithelium Anatomy 0.000 description 1
- 229940082789 erbitux Drugs 0.000 description 1
- 229960002061 ergocalciferol Drugs 0.000 description 1
- AAKJLRGGTJKAMG-UHFFFAOYSA-N erlotinib Chemical compound C=12C=C(OCCOC)C(OCCOC)=CC2=NC=NC=1NC1=CC=CC(C#C)=C1 AAKJLRGGTJKAMG-UHFFFAOYSA-N 0.000 description 1
- 229960001433 erlotinib Drugs 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 201000005884 exanthem Diseases 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 235000013376 functional food Nutrition 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 244000005709 gut microbiome Species 0.000 description 1
- 230000007407 health benefit Effects 0.000 description 1
- 230000008821 health effect Effects 0.000 description 1
- 229940022353 herceptin Drugs 0.000 description 1
- 239000008240 homogeneous mixture Substances 0.000 description 1
- 229940048921 humira Drugs 0.000 description 1
- 239000000017 hydrogel Substances 0.000 description 1
- 229930005346 hydroxycinnamic acid Natural products 0.000 description 1
- DEDGUGJNLNLJSR-UHFFFAOYSA-N hydroxycinnamic acid group Chemical class OC(C(=O)O)=CC1=CC=CC=C1 DEDGUGJNLNLJSR-UHFFFAOYSA-N 0.000 description 1
- 235000010359 hydroxycinnamic acids Nutrition 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 229910052816 inorganic phosphate Inorganic materials 0.000 description 1
- 239000002198 insoluble material Substances 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 150000002576 ketones Chemical group 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 208000019423 liver disease Diseases 0.000 description 1
- DLBFLQKQABVKGT-UHFFFAOYSA-L lucifer yellow dye Chemical compound [Li+].[Li+].[O-]S(=O)(=O)C1=CC(C(N(C(=O)NN)C2=O)=O)=C3C2=CC(S([O-])(=O)=O)=CC3=C1N DLBFLQKQABVKGT-UHFFFAOYSA-L 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 239000002539 nanocarrier Substances 0.000 description 1
- 210000003739 neck Anatomy 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 239000002417 nutraceutical Substances 0.000 description 1
- 235000021436 nutraceutical agent Nutrition 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 210000004798 organs belonging to the digestive system Anatomy 0.000 description 1
- 235000016046 other dairy product Nutrition 0.000 description 1
- 210000001672 ovary Anatomy 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 210000002307 prostate Anatomy 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 206010037844 rash Diseases 0.000 description 1
- 229940116176 remicade Drugs 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
- 102000003390 tumor necrosis factor Human genes 0.000 description 1
- 210000003556 vascular endothelial cell Anatomy 0.000 description 1
- 235000001892 vitamin D2 Nutrition 0.000 description 1
- 239000011653 vitamin D2 Substances 0.000 description 1
- MECHNRXZTMCUDQ-RKHKHRCZSA-N vitamin D2 Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)/C=C/[C@H](C)C(C)C)=C\C=C1\C[C@@H](O)CCC1=C MECHNRXZTMCUDQ-RKHKHRCZSA-N 0.000 description 1
- 235000005282 vitamin D3 Nutrition 0.000 description 1
- 239000011647 vitamin D3 Substances 0.000 description 1
- QYSXJUFSXHHAJI-YRZJJWOYSA-N vitamin D3 Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C\C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-YRZJJWOYSA-N 0.000 description 1
- 229940021056 vitamin d3 Drugs 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 239000002699 waste material Substances 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/12—Ketones
- A61K31/121—Ketones acyclic
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23J—PROTEIN COMPOSITIONS FOR FOODSTUFFS; WORKING-UP PROTEINS FOR FOODSTUFFS; PHOSPHATIDE COMPOSITIONS FOR FOODSTUFFS
- A23J3/00—Working-up of proteins for foodstuffs
- A23J3/04—Animal proteins
- A23J3/08—Dairy proteins
- A23J3/10—Casein
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/115—Fatty acids or derivatives thereof; Fats or oils
- A23L33/12—Fatty acids or derivatives thereof
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
- A23L33/19—Dairy proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Liposomes
- A61K9/1276—Globules of milk or constituents thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1658—Proteins, e.g. albumin, gelatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/06—Free radical scavengers or antioxidants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nutrition Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Biochemistry (AREA)
- Communicable Diseases (AREA)
- Diabetes (AREA)
- Oncology (AREA)
- Zoology (AREA)
- Dispersion Chemistry (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Rheumatology (AREA)
- Biomedical Technology (AREA)
- Botany (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Emergency Medicine (AREA)
- Obesity (AREA)
- Physical Education & Sports Medicine (AREA)
- Psychiatry (AREA)
- Endocrinology (AREA)
- Hospice & Palliative Care (AREA)
- Virology (AREA)
Description
本出願は、2013年3月15日出願の、米国仮特許出願番号61/788,200の優先権の恩典を主張する。適用可能な法律および/または規則に許容されるところで、その内容は参照により本明細書に組み入れられる。
この出願は、キャリア組成物を用いる治療用化合物の生物学的利用能を向上させるための産物および方法に関する。より具体的には、本発明は、たとえば、カゼインミセルを用いる、疎水性フェノール化合物といった化合物の生物学的利用能を向上するための産物および方法に関する。
植物由来化合物といった天然資源からの化合物を含む数多くの化合物は、これらが十分に溶解性ではなく、細胞に容易に取り込まれず、消化器官で容易に分解/破壊されるなどの理由で、対象により消費されたときにそれらの完全な恩恵を与えない。換言すれば、これらは、他のタイプの化合物に比べて生物学的利用能が低い。このような化合物の1つの例は、クルクミン((1E,6E)−1,7−ビス(4−ヒドロキシ−3−メトキシフェニル)−1,6−ヘプタジエン−3,5−ジオン)、ターメリック根茎に由来する疎水性ポリフェノールである。クルクミンは、ターメリックの活性成分として同定され、その有益な健康特性により長年の間使われてきた。過去数年にわたり、研究者らは、それが、抗酸化活性、抗炎症活性、抗ウイルス活性、抗菌活性、抗真菌活性、および抗ガン活性といった各種の恩恵を与えることを確認している。各種の研究に基づけば、クルクミンは、糖尿病、アレルギー、関節炎、アルツハイマー症、および他の慢性疾患の治療のための治療可能性を有することが示唆されている。著者らのあるグループは、「クルクミンは、近年発見された腫瘍壊死因子遮断薬(たとえば、HUMIRA(登録商標)、REMICADE(登録商標)、およびENBREL(登録商標))、血管内皮細胞増殖因子遮断薬(たとえば、AVASTIN(登録商標))、ヒト上皮成長因子受容体遮断薬(たとえば、ERBITUX(登録商標)、ERLOTINIB(登録商標)、およびGEFTINIB(登録商標))、およびHER2遮断薬(たとえば、HERCEPTIN(登録商標))と類似の活性を奏する」と結論している。(Aggarwal, B.B. etal., Curcumin: the Indian solid gold. Adv Exp Med Biol. (2007) 595:1-75. (非特許文献1))
[本発明1001]
以下の工程を含む、少なくとも1つの標的化合物のより生物学的に利用可能な形態を製造する方法:
(a)乳タンパク質濃縮物の溶液を、華氏約32度〜華氏約55度に冷却する工程;
(b)前記溶液に、約0.1μm〜約50μmの粒径を有する1つまたは複数の標的化合物を混合し、標的化合物/乳タンパク質濃縮物の溶液を形成する工程;
(c)標的化合物/乳タンパク質濃縮物の溶液を加温して混合する工程;
(d)標的化合物/乳タンパク質濃縮物の溶液を低温殺菌する工程;および、
(e)標的化合物/乳タンパク質濃縮物の溶液を乾燥する工程。
[本発明1002]
乳タンパク質濃縮物が、85%のタンパク質を含む、本発明1001の方法。
[本発明1003]
少なくとも1つの標的化合物が、疎水性化合物である、本発明1001の方法。
[本発明1004]
少なくとも1つの標的化合物が、フェノール化合物である、本発明1001の方法。
[本発明1005]
少なくとも1つの治療用標的化合物が、フェノール酸である、本発明1004の方法。
[本発明1006]
少なくとも1つの治療用標的化合物が、フラボノイドである、本発明1001の方法。
[本発明1007]
少なくとも1つの治療用標的化合物が、クルクミン、合成クルクミン、クルクミン類縁体、クルクミノイド、少なくとも1つのアジュバント分子と複合したクルクミン、およびこれらの組合せからなる群から選ばれる、本発明1001の方法。
[本発明1008]
乳タンパク質濃縮物の溶液が、約5〜約35%の溶液である、本発明1001の方法。
[本発明1009]
約0.1μmから約50μmの粒径が、粉砕によって製造される、本発明1001の方法。
[本発明1010]
標的化合物/乳タンパク質濃縮物の溶液を乾燥する工程が、噴霧乾燥を含む、本発明1001の方法。
[本発明1011]
冷却する工程が、華氏約32度〜華氏約55度の温度で、約1分〜約20時間の間、乳タンパク質濃縮物の溶液を冷却及び保持する工程を含む、本発明1001の方法。
[本発明1012]
冷却する工程が、華氏約32度〜華氏約55度の温度で、約30分〜約2時間の間、乳タンパク質濃縮物の溶液を冷却及び保持する工程を含む、本発明1001の方法。
[本発明1013]
以下の工程を含む、少なくとも1つの標的化合物を、少なくとも1つのカゼインミセルと結合して製造する方法:
(a)乳タンパク質濃縮物の溶液を、華氏約32度〜華氏約55度に冷却する工程;
(b)前記溶液に、約0.1μm〜約50μmの粒径を有する1つまたは複数の標的化合物を混合し、標的化合物/乳タンパク質濃縮物の溶液を形成する工程;
(c)標的化合物/乳タンパク質濃縮物の溶液を加温して混合する工程;
(d)標的化合物/乳タンパク質濃縮物の溶液を低温殺菌する工程;および、
(e)標的化合物/乳タンパク質濃縮物の溶液を乾燥する工程。
[本発明1014]
以下の工程を含む、ミセル結合クルクミン産物を作成する方法:
(a)乳タンパク質濃縮物の溶液を、華氏約32度〜華氏約55度に冷却する工程;
(b)前記溶液に、約0.1μm〜約50μmの粒径に粉砕されているクルクミン粉末を混合し、クルクミン/乳タンパク質濃縮物の溶液を形成する工程;
(c)クルクミン/乳タンパク質濃縮物の溶液を加温して混合する工程;
(d)クルクミン/乳タンパク質濃縮物の溶液を低温殺菌する工程;および、
(e)クルクミン/乳タンパク質濃縮物の溶液を噴霧乾燥して、ミセル結合クルクミン産物を製造する工程。
本発明者らは、1つまたは複数の標的化合物をカゼインミセルと結合させ、経口投与により投与されたとき、より低い溶解度および/または細胞取込みを一般に示す化合物の生物学的利用能を向上させるための方法を開発し、該方法は、乳タンパク質濃縮物の溶液を、華氏約32度〜華氏約55度に冷却する工程;前記溶液に、約0.1μm〜約50μmの粒径を有する1つまたは複数の標的化合物を混合し、標的化合物/乳タンパク質濃縮物の溶液を形成する工程;標的化合物/乳タンパク質濃縮物の溶液を加温して混合する工程;標的化合物/乳タンパク質濃縮物の溶液を低温殺菌する工程;および、標的化合物/乳タンパク質濃縮物の溶液を乾燥する工程を含む。別の局面において、乳タンパク質濃縮物は、少なくとも約80%のタンパク質の乳タンパク質濃縮物であってもよい。いくつかの局面において、乳タンパク質濃縮物は、少なくとも約85%のタンパク質の乳タンパク質濃縮物であってもよい。さらに、脱脂粉乳が、乳タンパク質濃縮物の代わりに、または乳タンパク質濃縮物とともに用いられてもよい。標的化合物は、固体形態または液体形態を含み、および油の形態であってもよい。別の局面において、約0.1μm〜約50μmの粒径は、1つまたは複数の標的化合物の固体形態を粉砕することにより達成されてもよい。
Claims (9)
- 以下の工程を含む、クルクミンをカゼインミセルと結合して、より生物学的に利用可能なミセル結合クルクミン産物を製造する方法:
(a)乳タンパク質濃縮物の溶液を、華氏約32度〜華氏約55度に冷却する工程;
(b)前記溶液に、約0.1μm〜約50μmの粒径を有するクルクミンを混合し、クルクミン/乳タンパク質濃縮物の溶液を形成する工程;
(c)クルクミン/乳タンパク質濃縮物の溶液を加温して混合する工程;
(d)クルクミン/乳タンパク質濃縮物の溶液を低温殺菌する工程;および、
(e)クルクミン/乳タンパク質濃縮物の溶液を乾燥する工程。 - 乳タンパク質濃縮物が、85%のタンパク質を含む、請求項1に記載の方法。
- 乳タンパク質濃縮物の溶液が、約5〜約35%の溶液である、請求項1に記載の方法。
- 約0.1μmから約50μmの粒径が、粉砕によって製造される、請求項1に記載の方法。
- クルクミン/乳タンパク質濃縮物の溶液を乾燥する工程が、噴霧乾燥を含む、請求項1に記載の方法。
- 冷却する工程が、華氏約32度〜華氏約55度の温度で、約1分〜約20時間の間、乳タンパク質濃縮物の溶液を冷却及び保持する工程を含む、請求項1に記載の方法。
- 冷却する工程が、華氏約32度〜華氏約55度の温度で、約30分〜約2時間の間、乳タンパク質濃縮物の溶液を冷却及び保持する工程を含む、請求項1に記載の方法。
- 以下の工程を含む、クルクミンをカゼインミセルと結合して、ミセル結合クルクミン産物を製造する方法:
(a)乳タンパク質濃縮物の溶液を、華氏約32度〜華氏約55度に冷却する工程;
(b)前記溶液に、約0.1μm〜約50μmの粒径を有するクルクミンを混合し、クルクミン/乳タンパク質濃縮物の溶液を形成する工程;
(c)クルクミン/乳タンパク質濃縮物の溶液を加温して混合する工程;
(d)クルクミン/乳タンパク質濃縮物の溶液を低温殺菌する工程;および、
(e)クルクミン/乳タンパク質濃縮物の溶液を乾燥する工程。 - 以下の工程を含む、クルクミンをカゼインミセルと結合して、ミセル結合クルクミン産物を作成する方法:
(a)乳タンパク質濃縮物の溶液を、華氏約32度〜華氏約55度に冷却する工程;
(b)前記溶液に、約0.1μm〜約50μmの粒径に粉砕されているクルクミン粉末を混合し、クルクミン/乳タンパク質濃縮物の溶液を形成する工程;
(c)クルクミン/乳タンパク質濃縮物の溶液を加温して混合する工程;
(d)クルクミン/乳タンパク質濃縮物の溶液を低温殺菌する工程;および、
(e)クルクミン/乳タンパク質濃縮物の溶液を噴霧乾燥して、ミセル結合クルクミン産物を製造する工程。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201361788200P | 2013-03-15 | 2013-03-15 | |
US61/788,200 | 2013-03-15 | ||
PCT/US2014/030685 WO2014145851A1 (en) | 2013-03-15 | 2014-03-17 | Product and method for improving bioavailability of therapeutic compounds |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2018246450A Division JP2019077699A (ja) | 2013-03-15 | 2018-12-28 | 治療用化合物の生物学的利用能を向上させるための産物および方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2016515535A JP2016515535A (ja) | 2016-05-30 |
JP6548632B2 true JP6548632B2 (ja) | 2019-07-24 |
Family
ID=51530032
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2016503442A Expired - Fee Related JP6548632B2 (ja) | 2013-03-15 | 2014-03-17 | 治療用化合物の生物学的利用能を向上させるための産物および方法 |
JP2018246450A Pending JP2019077699A (ja) | 2013-03-15 | 2018-12-28 | 治療用化合物の生物学的利用能を向上させるための産物および方法 |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2018246450A Pending JP2019077699A (ja) | 2013-03-15 | 2018-12-28 | 治療用化合物の生物学的利用能を向上させるための産物および方法 |
Country Status (8)
Country | Link |
---|---|
US (1) | US9452146B2 (ja) |
EP (1) | EP2968070B1 (ja) |
JP (2) | JP6548632B2 (ja) |
CN (1) | CN105491988A (ja) |
AU (1) | AU2014232456B2 (ja) |
CA (1) | CA2911020A1 (ja) |
NZ (1) | NZ713235A (ja) |
WO (1) | WO2014145851A1 (ja) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP6548632B2 (ja) | 2013-03-15 | 2019-07-24 | グランビア ニュートリショナルズ (アイルランド) リミテッド | 治療用化合物の生物学的利用能を向上させるための産物および方法 |
CN114246849A (zh) * | 2014-05-12 | 2022-03-29 | 奥斯生化药剂公司 | 姜黄素-肽缀合物及其制剂 |
US10188135B2 (en) | 2015-11-04 | 2019-01-29 | Stokley-Van Camp, Inc. | Method for inducing satiety |
CN109419795B (zh) * | 2017-08-28 | 2021-02-26 | 四川九章生物科技有限公司 | 一种治疗肿瘤坏死因子家族相关疾病的联合用药物 |
AU2022276114A1 (en) * | 2021-05-19 | 2023-11-16 | Arla Foods Amba | High protein, micellar casein-containing nutritional liquids enriched with catechin-compounds and method of production |
Family Cites Families (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DK546289D0 (da) * | 1989-11-02 | 1989-11-02 | Danochemo As | Carotenoidpulvere |
EP0748591B1 (fr) * | 1995-06-16 | 2001-10-17 | Societe Des Produits Nestle S.A. | Caséines micellaires fluorées |
DE19919751A1 (de) | 1999-04-29 | 2000-11-09 | Basf Ag | Stabile, wäßrige Dispersionen und stabile, wasserdispergierbare Trockenpulver von Xanthophyllen, deren Herstellung und Verwendung |
DE60222160T2 (de) | 2001-10-12 | 2008-06-12 | Elan Pharma International Ltd., Athlone | Zusammensetzungen mit einer kombination aus eigenschaften sofortiger freisetzung und kontrollierter freisetzung |
US6923995B2 (en) * | 2002-03-27 | 2005-08-02 | Jay C. Highman | Rice protein concentrate based organic nutritional formula |
PL1957041T3 (pl) | 2005-11-22 | 2011-02-28 | Nestec Sa | Emulsja olej-w-wodzie i jej zastosowanie dla nadania funkcji |
PL1839498T3 (pl) | 2006-03-27 | 2011-09-30 | Nestec Sa | Podłoże z białek serwatki do dostarczania środków aktywnych |
US20080026983A1 (en) * | 2006-07-28 | 2008-01-31 | Gardiner Paul T | Compositions and methods for alleviating joint pain and improving joint flexibility |
US8642736B2 (en) * | 2006-08-09 | 2014-02-04 | Dsm Ip Assets B. V. | Casein complexes |
WO2008139952A1 (ja) | 2007-05-15 | 2008-11-20 | National University Corporation Nagoya University | 微小管破壊剤及びそれを含有する癌細胞増殖抑制剤 |
JP2009040722A (ja) | 2007-08-09 | 2009-02-26 | Fujifilm Corp | 複数のタンパク質からなるカゼインナノ粒子 |
WO2009101612A2 (en) | 2008-02-11 | 2009-08-20 | Technion Research And Development Foundation Ltd. | Beta-casein assemblies for enrichment of food and beverages and methods of preparation thereof |
US8871276B2 (en) | 2008-02-11 | 2014-10-28 | Technion Research And Development Foundation Ltd. | Beta-casein assemblies for mucosal delivery of therapeutic bioactive agents |
US20110045092A1 (en) * | 2008-02-11 | 2011-02-24 | Livney Yoav D | Casein particles encapsulating therapeutically active agents and uses thereof |
US8865223B2 (en) | 2008-02-11 | 2014-10-21 | Technion Research And Development Foundation Ltd. | Beta-casein assemblies for mucosal delivery of therapeutic bioactive agents |
CN101816418B (zh) * | 2009-11-24 | 2012-07-18 | 北京三元食品股份有限公司 | 一种益生菌微胶囊及其制备方法 |
WO2011100983A1 (en) * | 2010-02-17 | 2011-08-25 | El-Sayed Ameen Mahmoud Rezq | Casein, a novel curcumin drug carrier system |
DK2540169T3 (en) * | 2010-02-26 | 2016-10-03 | Univ Navarra | Nanoparticles for encapsulating compositions, their preparation and use of same. |
CN102126938B (zh) * | 2010-12-15 | 2013-03-27 | 厦门大学 | 一种姜黄素类似物及其制备方法和应用 |
CN102600063B (zh) * | 2011-06-09 | 2013-10-23 | 天津大学 | 一种高载药量姜黄素胶束的制备方法 |
CN102512404B (zh) | 2011-11-18 | 2014-05-07 | 上海交通大学 | 一种姜黄素类化合物肺靶向制剂及其制备方法与应用 |
CN102743336A (zh) * | 2012-07-04 | 2012-10-24 | 浙江大学 | 姜黄素壳聚糖硬脂酸嫁接物胶束的制备方法及其应用 |
JP6548632B2 (ja) | 2013-03-15 | 2019-07-24 | グランビア ニュートリショナルズ (アイルランド) リミテッド | 治療用化合物の生物学的利用能を向上させるための産物および方法 |
-
2014
- 2014-03-17 JP JP2016503442A patent/JP6548632B2/ja not_active Expired - Fee Related
- 2014-03-17 US US14/217,047 patent/US9452146B2/en not_active Expired - Fee Related
- 2014-03-17 CA CA2911020A patent/CA2911020A1/en not_active Abandoned
- 2014-03-17 AU AU2014232456A patent/AU2014232456B2/en not_active Ceased
- 2014-03-17 EP EP14762887.9A patent/EP2968070B1/en not_active Revoked
- 2014-03-17 NZ NZ713235A patent/NZ713235A/en not_active IP Right Cessation
- 2014-03-17 WO PCT/US2014/030685 patent/WO2014145851A1/en active Application Filing
- 2014-03-17 CN CN201480023195.XA patent/CN105491988A/zh active Pending
-
2018
- 2018-12-28 JP JP2018246450A patent/JP2019077699A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
US9452146B2 (en) | 2016-09-27 |
AU2014232456B2 (en) | 2018-11-15 |
JP2019077699A (ja) | 2019-05-23 |
EP2968070A1 (en) | 2016-01-20 |
JP2016515535A (ja) | 2016-05-30 |
EP2968070B1 (en) | 2019-12-18 |
AU2014232456A1 (en) | 2015-11-05 |
CA2911020A1 (en) | 2014-09-18 |
US20140275283A1 (en) | 2014-09-18 |
EP2968070A4 (en) | 2016-10-26 |
NZ713235A (en) | 2019-12-20 |
CN105491988A (zh) | 2016-04-13 |
WO2014145851A1 (en) | 2014-09-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2019077699A (ja) | 治療用化合物の生物学的利用能を向上させるための産物および方法 | |
Maurya et al. | Vitamin D microencapsulation and fortification: Trends and technologies | |
CN103369975B (zh) | 具有减少的涩味的乳清蛋白组合物 | |
JP6016363B2 (ja) | 脳神経細胞新生剤 | |
US20170258830A1 (en) | Compositions and methods for the maintenance of adequate iron intake in a mammal | |
WO2008069276A1 (ja) | 癌治療剤および発癌抑制剤 | |
Wang et al. | The stability and bioavailability of curcumin loaded α-lactalbumin nanocarriers formulated in functional dairy drink | |
Arranz et al. | Improved bioavailability of supercritical rosemary extract through encapsulation in different delivery systems after in vitro digestion | |
Chang et al. | A dual function of ferritin (animal and plant): its holo form for iron supplementation and apo form for delivery systems | |
CN105682481A (zh) | 包含胆碱及其衍生物的组合物、其用途以及其制备方法 | |
Elías‐Argote et al. | Dairy ingredients containing milk fat globule membrane: description, composition, and industrial potential | |
CA2537544A1 (en) | Milk fractions and milk preparations for treating and/or preventing cox-2 mediated diseases | |
Ren et al. | Functional improvement of (−)-epicatechin gallate and piceatannol through combined binding to β-lactoglobulin: Enhanced effect of heat treatment and nanoencapsulation | |
KR102050578B1 (ko) | 산양유를 함유한 액상 조제유 조성물 | |
TWI703931B (zh) | 含有山羊奶的液體調製乳組合物及其製造方法 | |
KR101640890B1 (ko) | 산양유를 함유한 액상 조제유 조성물 | |
JP2016159206A (ja) | 生理活性物質の担持力を向上させたナノ粒子の製造方法 | |
Muthusamy | Milk Fat Globular Membrane: Composition, Structure, Isolation, Technological Significance and Health Benefits | |
Soares et al. | Milking the milk: Exploiting the full potential of milk constituents for nature-derived delivery systems | |
WO2017187540A1 (ja) | エーテル型グリセロリン脂質含有組成物及びその製造方法 | |
EP2046135B1 (de) | Polyphenol-peptid-zusammensetzung und ihre verwendung zur unterstützung der darmgesundheit | |
TWI691334B (zh) | 內服用組成物、製劑、與用途 | |
Ghosh et al. | Nanofortification: An Emerging Technique for Enhancement of the Functionality of Foods with Ample Future Scopes | |
JP2016216369A (ja) | 前立腺肥大症改善剤 | |
Choki | Fate of hydroxyapatite nano particles during in vitro gastrointestinal digestion: a thesis presented in partial fulfilment of the requirements for the degree of Master in Food Technology at Massey University, Riddet Institute and Massey Institute of Food Science and Technology, Palmerston North, New Zealan |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20161221 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20171002 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20171228 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20180329 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20180830 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20181228 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20181228 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20190307 |
|
A911 | Transfer to examiner for re-examination before appeal (zenchi) |
Free format text: JAPANESE INTERMEDIATE CODE: A911 Effective date: 20190313 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20190605 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20190625 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 6548632 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
LAPS | Cancellation because of no payment of annual fees |